FeedKind® Dramatically Reduces Shrimp Vibration and Improves Survival During EMS Challenge | Nation / World


SAN MATEO, Calif .– (BUSINESS WIRE) – November 2, 2021–

Calysta, Inc. New scientific studies show that the well-being of shrimp could be dramatically improved if fed with Calysta’s FeedKind ® protein, the food ingredient that dramatically reduces the risk of early mortality syndrome.

EMS is one of the biggest issues facing shrimp farming today, having cost the industry billions of dollars since it was first identified in Asia in 2009.

But a new study on the effectiveness of the unicellular protein of Calysta as a food ingredient for shrimp by Kasetsart University has shown a significant improvement in the immune response of shrimp to the disease – with survival rates of up to ‘to 100% after 15 days of exposure, compared to only 76.7% of those fed a traditional fishmeal food.

FeedKind protein is a family of natural, sustainable and traceable food ingredients for fish, livestock and pets, produced by fermenting natural gas with natural bacteria. It uses no arable land and little water in its production, supporting global food security and helping to feed a growing population in a sustainable way.

Allan LeBlanc, Vice President, Head of Aquaculture at Calysta, said: “Outbreaks remain one of the biggest challenges in aquaculture today. EMS in particular has caused more than $ 20 billion in losses to the shrimp industry over the past decade, and disease management and prevention is one of the industry’s top priorities.

“FeedKind’s ability to activate the innate immune system of shrimp could transform the industry. As a key ingredient in functional foods, it can form the backbone of a comprehensive disease prevention strategy for farmers, while improving animal health and increasing yield.

“With a growing world population and increasing demand for protein, being able to produce more food with less is absolutely essential to help us maximize existing resources and improve global food security. “

The results of the new trial on the efficacy of Calysta’s unicellular protein feed in farmed shrimp also show that FeedKind-based feeds are just as effective in promoting the growth and survival of shrimp as traditional feeds in farmed shrimp. fish meal base.

The study, carried out by Dr Orapint at the Aquatic Nutrition and Feeding Laboratory, Department of Aquaculture, Faculty of Fisheries, Kasetsart University, Bangkok, Thailand, is published today in the journal, Frontiers in marine sciences. The study said: “FeedKind does not inhibit growth performance, feed efficiency or survival of shrimp. Additionally, the shrimp in this study demonstrated increased tolerance to disease when confronted with Vibrio. , indicating that the FeedKind protein may help promote a robust immune response.

Since its discovery in 2009, EMS has wreaked havoc on Asian aquaculture markets. In China, production was reduced by up to 80% in some areas, while Thailand reported $ 11.5 billion in losses due to the disease between 2010 and 2016. Vietnam experienced similar problems, citing losses of over $ 2.5 billion.

The FeedKind study saw Penaeus vannamei shrimp fed a variety of diets, from a control diet of traditional fishmeal foods, to diets with increasing amounts of FeedKind protein to replace fishmeal. ; at 33%, 66% and 100% – up to a total of 15% feed.

The shrimp then spent 15 days continuously exposed to the causative agent of EMS, Vibrio parahaemolyticus. All shrimp on FeedKind based diets showed higher survival rates compared to fishmeal based foods, from 76.7% in the control, to 86.7% at 5% FeedKind, 96, 7% to 10% FeedKind and 100% at 15% FeedKind concentration.

The current study has shown that fishmeal can be completely replaced in shrimp diets with FeedKind. In addition, replacement of fishmeal with a meal protein from methanotrophic bacteria, FeedKind, followed by natural challenge with V. parahaemolyticus improved survival.

Calysta’s 50/50 joint venture with Adisseo, Calysseo, is building the world’s first commercial FeedKind production plant in Chongqing, China, with the completion of the first 20,000 tonnes per year plant scheduled for the year next and its expansion shortly thereafter.

Investors in Calysta include bp, Adisseo and AquaSpark. For more information on Calysta, visit www.Calysta.com. Sign up for the newsletter at www.FeedKind.com.

About Calysta

Calysta, Inc., San Mateo, CA, is a biotechnology company working towards a future where the world’s growing population ensures food security. Calysta’s goal is to do more with less by fermenting natural gas to create new food products, creating sustainable, high-value nutritional ingredients that don’t interfere with the human food chain.

FeedKind®, is made using very little water and no farmland by fermenting natural gas, an abundant source of energy, to create a safe, nutritious, traceable and affordable protein. Produced through natural fermentation, it is non-GMO, competitively priced with existing protein sources and produced to the highest quality standards. FeedKind has been commercially validated through extensive customer testing in aquaculture, agriculture and pet food.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20211102005834/en/

CONTACT: Calysta –Steven Flanagan, (+44) 141 343 3250 orsflanagan@webershandwick.com


Calysta Media Information, info@calysta.com



SOURCE: Calysta, Inc.

Copyright Business Wire 2021.

PUB: 11/02/2021 20:01 / DISC: 11/02/2021 20:02


Source link

Leave A Reply

Your email address will not be published.